Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment

In September 2022, the NICE Topic Selection Oversight Panel (TSOP) met to decide if the topic should proceed to guidance development. The panel utilised the selection and routing considerations within section 6.2 of the NICE health technology evaluation topic selection manual. The panel considered the appropriateness for medical technology or technology appraisal guidance and heard that gameChange is likely to have clinical benefit and may address a notable unmet need. But there are uncertainties around whether gameChange would be cost saving or cost effective based on the evidence provided. The panel therefore concluded that an Early Value Assessment (EVA) of the technology would allow for further evidence generation to address these gaps in evidence before final NICE guidance.